ABANDONED - NO STATEMENT OF USE FILED
no statement of use filed
on 11 Oct 2021
Last Applicant/ Owned by
One Johnson & Johnson Plaza
New Brunswick
NJ
08933
Serial Number
87876523 filed on 13th Apr 2018
Registration Number
N/A
Correspondent Address
Cheryl L. Foytlin
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
APELFRO
Human pharmaceutical preparations for the prevention and treatment of viral diseases, auto-immune and inflammatory diseases, cardiovascular and pulmonary diseases, central nervous system diseases, peripheral neurological system diseases, pain, dermatologic diseases, gastro-intestinal diseases, infectious-related diseases, metabolic diseases, oncologic diseases, ophthalmic diseases, respiratory dis Read More
Classification Information
Class [005]
Pharmaceutical Products
Human pharmaceutical preparations for the prevention and treatment of viral diseases, auto-immune and inflammatory diseases, cardiovascular and pulmonary diseases, central nervous system diseases, peripheral neurological system diseases, pain, dermatologic diseases, gastro-intestinal diseases, infectious-related diseases, metabolic diseases, oncologic diseases, ophthalmic diseases, respiratory diseases, digital ulcers, and cerebrovascular diseases; vaccines; anxiolytics; anti-allergics; anti-infectives
Mark Details
Serial Number
No 87876523
Mark Type
No Service/Collective Mark
Attorney Docket Number
No T43837US1
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 12th Oct 2021 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
| 11th Oct 2021 | ABANDONMENT - NO USE STATEMENT FILED |
| 19th Dec 2020 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| 18th Dec 2020 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| 18th Dec 2020 | EXTENSION 5 GRANTED |
| 02th Dec 2020 | TEAS EXTENSION RECEIVED |
| 02th Dec 2020 | EXTENSION 5 FILED |
| 22nd Aug 2020 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| 20th Aug 2020 | EXTENSION 4 FILED |
| 20th Aug 2020 | EXTENSION 4 GRANTED |